Integrating ENGagement and Adherence Goals Upon Entry iENGAGE to Control HIV
|Study Design:||Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
|Official Title:||Integrating ENGagement and Adherence Goals Upon Entry iENGAGE to Control HIV|
- Viral load suppression (<200c/ml)among patients newly initiating outpatient HIV medical care [ Time Frame: 48 week ] [ Designated as safety issue: No ]
- Viremia copy years (VCY) [ Time Frame: 96 week ] [ Designated as safety issue: No ]VCY is the area under the curve estimate of cumulative VL burden
|Study Start Date:||December 2013|
|Estimated Study Completion Date:||March 2017|
|Estimated Primary Completion Date:||April 2016 (Final data collection date for primary outcome measure)|
No Intervention: Control
Control arm participants will receive standard clinical care (i.e. receive usual clinic treatment)
Experimental: Motivation Behavioral Technique
Behavioral: 4 sessions of tailored, interactive agenda based on behavioral motivational interviewing (MI) techniques. Each iENGAGE intervention session includes: interventionist-delivered educational content for managing HIV medical care appointment-keeping and information sessions for learning to manage HIV medications. The goal of this intervention is for the participant to establish early behaviors that help him/her to arrive at scheduled medical appointments and learn to take medications as prescribed during the initial year of HIV care in order in order to achieve viral suppression and improve overall health.
Behavioral: Based on behavioral motivational interviewing (MI) technique
In addition to receiving standard clinic care, the intervention will have a tailored, interactive agenda for each of the 4 sessions based on behavioral motivational interviewing (MI) technique. The goal of this intervention is for the participant to establish early behaviors that help him/her to arrive at scheduled medical appointments and learn to take medications as prescribed during the initial year of HIV care in order to in order to achieve viral suppression and improve overall health.
The Centers for Disease Control's Retention In Care (CDC RIC) and the Participating and Communicating Together (PACT) antiretroviral therapy (ART) adherence interventions have shown success in the literature, and they are well suited to target the two essential HIV adherence behaviors needed to achieve better overall health: HIV medical visit adherence and ART adherence. While these original interventions target each of these behaviors separately, the comprehensive iENGAGE intervention combines these two approaches to address the experience of an individual who is initiating HIV care. Upon entry to care, knowledge, motivation, and skills for adherence to HIV medical visits and ART must be learned rapidly. Jointly targeting these behaviors offers a distinct advantage over addressing them separately.
iENGAGE integrates CDC RIC and PACT through their common intervention targets with the assistance of trained interventionists, who will maintain contact with the new patient to educate and assist with reinforcing the importance of adherence to care. While the actions required to attend HIV medical care appointments and take medications properly are distinct, each is influenced by an individual's personal motivation and skills for self-management of HIV infection and overall health; these principles are the focus of the intervention sessions for this protocol .
During this intervention, our team will make every effort to protect all participants' confidential and private information in order to minimize possible study-associated risks. In addition, the follow up measurement plan for this study is unique, as it aims to utilize the X060831001: Unsolicited R24 for the CFAR Network of Integrated Clinical Sciences, CNICS, PI Michael Saag) secure electronic data infrastructure, which has existing defined protocols for the protection of human subjects data, including a data management core that is housed at the collaborating site at the University of Washington.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01900236
|Contact: Riddhi Modi||2059341284||Rmodi@uab.edu|
|United States, Alabama|
|University of Alabama at Birmingham||Recruiting|
|Birmingham, Alabama, United States, 35294|
|Principal Investigator: Michael J Mugavero, MD, MHSc|
|United States, Maryland|
|The Johns Hopkins HIV Care Program||Recruiting|
|Baltimore, Maryland, United States, 21205|
|United States, North Carolina|
|UNC Infectious Diseases Clinic||Recruiting|
|Chapel Hill, North Carolina, United States, 27599|
|United States, Washington|
|• University of Washington||Recruiting|
|Seattle, Washington, United States, 98104|
|Principal Investigator:||Michael J Mugavero, MD||University of Alabama at Birmingham|